Worth reading
14Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Items stated in the management plan
Publication date3 September 2026
This document does not state the plan name, plan period, or numerical targets.
Key initiatives
01Obtaining U.S. FDA clearance for Accelagen™ Plus Surgical Matrix
02Beginning commercial sales in the United States in the first quarter of 2027
03Transitioning to a private-label business structure
Reason for revision or withdrawal
We are fundamentally reviewing the business operations of the Medtech segment in order to overcome its current challenge of relatively low profit margins and transform it into a high-profitability business.
| Item | Details |
|---|---|
| Key initiatives | Obtaining U.S. FDA clearance for Accelagen™ Plus Surgical Matrix, Beginning commercial sales in the United States in the first quarter of 2027, Transitioning to a private-label business structure |
| Reason for revision or withdrawal | We are fundamentally reviewing the business operations of the Medtech segment in order to overcome its current challenge of relatively low profit margins and transform it into a high-profitability business. |
| Publication date | 3 September 2026 |
Items this document does not state (22)
Plan namePlan periodProgress against the planSales TargetOperating profit targetOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSegment targetNon-financial targetsPlan assumptionsResults under the previous planSize of the Target MarketRisks identifiedDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company explained that it is fundamentally reviewing its business operations in order to overcome the challenge of the Medtech segment’s relatively low profit margins and transform it into a high-profitability business.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.